Program Type: Midwest CEPAC


Apr 2022 | Assessment

Interventions of Interest: casirivimab/imdevimab (Ronapreve™, Regeneron) sotrovimab (GlaxoSmithKline and Vir Biotechnology) molnupiravir (Merck) PF-07321332/ritonavir (PAXLOVID™, Pfizer) fluvoxamine (Investigator initiated) ICER is currently conducting a special assessment of outpatient treatments for COVID-19. COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. As of August 2021, there have been […]


Nov 2021 | Assessment

Interventions of Interest: Tezepelumab (Amgen, AstraZeneca) ICER’s Evidence Report Findings: Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year. At the November 19 virtual meeting, ICER’s independent appraisal committee will review the […]

Multiple Myeloma

Apr 2021 | Assessment

Interventions of Interest: idecabtagene vicleucel (Abecma®, Bristol-Myers Squibb, bluebird bio) ciltacabtagene autoleucel (Johnson & Johnson, Legend Biotech Corp) Belantamab mafodotin (Blenrep™, GlaxoSmithKline) The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for ide-cel, […]